New cancer clinical trial: A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.

Published on: June 12, 2025 at 11:00AM
Conditions: Solid Tumors; Refractory Cancer
Interventions: Drug: CBA-1535; Drug: CBA-1535+Pembrolizumab
Sponsors: Chiome Bioscience Inc.
Recruiting
https://ift.tt/Ei6rIjY A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.